1 completed, 1 enrolling by invitation, 1 terminated. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Enrolling by invitation 1, Terminated 1 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Hereditary Angioedema Attack: new trials by email Literature Review of Hereditary Angioedema Attack trials Research Report on Hereditary Angioedema Attack
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
| Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II Deucrictibant low dose, Deucrictibant high dose, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Terminated | Pharvaris Netherlands B.V. | 34 | 2022-04-19 | 2026-08-17 |
| Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Completed | Pharvaris Netherlands B.V. | 74 | 2021-02-03 | 2025-12-17 |
Angioedemas, Hereditary (3) · Hereditary Angioedema Types I and II (3) · Hereditary Angioedema Type III (1)
Angioedema (3) · Cardiovascular Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Hereditary Complement Deficiency Diseases (3) · Hypersensitivity (3) · Hypersensitivity, Immediate (3) · Immune System Diseases (3) · Immunologic Deficiency Syndromes (3) · Primary Immunodeficiency Diseases (3) · Skin Diseases (3) · Skin Diseases, Vascular (3) · Skin and Connective Tissue Diseases (3) · Urticaria (3) · Vascular Diseases (3)
Pharvaris Netherlands B.V. (3)
Bulgaria (3) · Canada (3) · Germany (3) · Italy (3) · Poland (3) · United Kingdom (3) · United States (3) · Austria (2) · Czechia (2) · France (2) · Hungary (2) · Israel (2) · Netherlands (2) · Spain (2) · Argentina (1)
Marc Riedl, MD (1) · Marcus Maurer, Prof MD (1)
2023 (1)